Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study

por Agiro, Abiy, Dwyer, Jamie P, Oluwatosin, Yemisi, Desai, Pooja
Publicado 2023

Impact of Sodium Zirconium Cyclosilicate Plus Renin–Angiotensin–Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study

por Dwyer, Jamie P., Agiro, Abiy, Desai, Pooja, Oluwatosin, Yemisi
Publicado 2023

Membranous glomerulopathy with superimposed pauci-immune necrotizing crescentic glomerulonephritis

por Fatima, Huma, Siew, Edward D., Dwyer, Jamie P., Paueksakon, Paisit
Publicado 2012

439. Iclaprim Use for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is Not Associated with Hyperkalemia: Phase 3 REVIVE Studies

por Huang, David B, Noviello, Stephanie S, Lodise, Thomas, McKinnell, James, Dwyer, Jamie P
Publicado 2019

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data

por Rodby, Roger A., Umanath, Kausik, Niecestro, Robert, Christopher Bond, T., Sika, Mohammed, Lewis, Julia, Dwyer, Jamie P.
Publicado 2015

Diabetic Proteinuria Revisited: Updated Physiologic Perspectives

por Heyman, Samuel N., Raz, Itamar, Dwyer, Jamie P., Weinberg Sibony, Roni, Lewis, Julia B., Abassi, Zaid
Publicado 2022

Anti-Phospholipase A2 Receptor in Nonlupus Patients with Membranous Nephropathy and Crescents

por Zuo, Yiqin, Cavalcante, Livia Barreira, Smelser, James Monroe, Sanghani, Neil, Dwyer, Jamie P., Lewis, Julia Breyer, Fogo, Agnes B.
Publicado 2021

Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials

por Canoy, Dexter, Copland, Emma, Nazarzadeh, Milad, Ramakrishnan, Rema, Pinho-Gomes, Ana-Catarina, Salam, Abdul, Dwyer, Jamie P, Farzadfar, Farshad, Sundström, Johan, Woodward, Mark, Davis, Barry R, Rahimi, Kazem
Publicado 2022

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes

por Moura, Filipe A., Berg, David D., Bellavia, Andrea, Dwyer, Jamie P., Mosenzon, Ofri, Scirica, Benjamin M., Wiviott, Stephen D., Bhatt, Deepak L., Raz, Itamar, Feinberg, Mark W., Braunwald, Eugene, Morrow, David A., Sabatine, Marc S.
Publicado 2023

Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants

por Supiano, Mark A., Lovato, Laura, Ambrosius, Walter T., Bates, Jeffrey, Beddhu, Srinivasan, Drawz, Paul, Dwyer, Jamie P., Hamburg, Naomi M., Kitzman, Dalane, Lash, James, Lustigova, Eva, Miracle, Cynthia M., Oparil, Suzanne, Raj, Dominic S., Weiner, Daniel E., Taylor, Addison, Vita, Joseph A., Yunis, Reem, Chertow, Glenn M., Chonchol, Michel
Publicado 2018

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

por Mosenzon, Ofri, Wiviott, Stephen D., Heerspink, Hiddo J.L., Dwyer, Jamie P., Cahn, Avivit, Goodrich, Erica L., Rozenberg, Aliza, Schechter, Meir, Yanuv, Ilan, Murphy, Sabina A., Zelniker, Thomas A., Gause-Nilsson, Ingrid A.M., Langkilde, Anna Maria, Fredriksson, Martin, Johansson, Peter A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Sabatine, Marc S., Raz, Itamar
Publicado 2021

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

por Mosenzon, Ofri, Raz, Itamar, Wiviott, Stephen D., Schechter, Meir, Goodrich, Erica L., Yanuv, Ilan, Rozenberg, Aliza, Murphy, Sabina A., Zelniker, Thomas A., Langkilde, Anna Maria, Gause-Nilsson, Ingrid A.M., Fredriksson, Martin, Johansson, Peter A., Wilding, John P.H., McGuire, Darren K., Bhatt, Deepak L., Leiter, Lawrence A., Cahn, Avivit, Dwyer, Jamie P., Heerspink, Hiddo J.L., Sabatine, Marc S.
Publicado 2022

Decentralized clinical trials in the trial innovation network: Value, strategies, and lessons learned

por Hanley, Daniel F., Bernard, Gordon R., Wilkins, Consuelo H., Selker, Harry P., Dwyer, Jamie P., Dean, J. Michael, Benjamin, Daniel Kelly, Dunsmore, Sarah E., Waddy, Salina P., Wiley, Kenneth L., Palm, Marisha E., Mould, W. Andrew, Ford, Daniel F., Burr, Jeri S., Huvane, Jacqueline, Lane, Karen, Poole, Lori, Edwards, Terri L., Kennedy, Nan, Boone, Leslie R., Bell, Jasmine, Serdoz, Emily, Byrne, Loretta M., Harris, Paul A.
Publicado 2023

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

por Wheeler, David C, Stefansson, Bergur V, Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z I, Chertow, Glenn M, Douthat, Walter, Dwyer, Jamie P, Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Górriz, José Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin-Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B, McMurray, John J V, Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D, Umanath, Kausik, Van Bui, Pham, Wittmann, István, Lindberg, Magnus, Sjöström, C David, Langkilde, Anna Maria, Heerspink, Hiddo J L
Publicado 2020